Indian pharma firm Gland Pharma registers a 16% rise in Q1FY25 consolidated revenue to Rs 1,401.7 crore, driven by US market growth.

Indian pharma company Gland Pharma reported a 16% increase in consolidated revenue to Rs 1,401.7 crore for Q1FY25, driven by a significant contribution from the US market, which saw a 27% revenue increase. Base business (ex-Cenexi) revenue grew 14% YoY to Rs 1,013.4 crore, and EBITDA increased 12% YoE to Rs 294.1 crore. The company is exploring acquisitions, in-licensing, and co-development opportunities to accelerate growth.

August 06, 2024
6 Articles

Further Reading